Joint partners forum for strengthening and aligning tb diagnosis and treatment

WHO Executive Board Room Geneva, 27-30 April 2015

GLI / GDI Partners Forum

Organized by the World Health Organization

Global TB Programme


JOINT PARTNERS FORUM FOR STRENGTHENING AND ALIGNING

TB DIAGNOSIS AND TREATMENT

JOINT PARTNERS FORUM FOR STRENGTHENING AND ALIGNING TB DIAGNOSIS AND TREATMENT

REPORT


27-30 April 2015

Geneva, Switzerland

Contents

List of abbreviations 4

Background 5

Session 1: Introduction 6

Session 2: Advancements and opportunities in diagnosis and treatment 9

Session 3: Introduction and access to new anti-TB drugs 12

Session 4: Implementing innovations 18

Session 5: Update on Xpert MTB/RIF implementation 22

Session 6: Joint TB and HIV services platforms and opportunities for TB/HIV integration 25

Session 7: Country Experiences in strengthening and aligning diagnosis and treatment 28

Session 8: Donor perspectives and strategies to strengthen and align diagnosis and treatment 33

Session 9: Initiatives to strengthen PMDT 36

Session 10: Symposium on regional GLI/GDI initiatives 39

List of participants 44

Photos cortesy of Ernesto Jaramillo and Medea Gegia

All presentations from the meeting are posted on the WHO website http://www.who.int/tb/laboratory/gli/en/

List of abbreviations

ARV	antiretroviral
Bdq	Bedaquiline
BRICS	Brazil, Russia, India, China and South Africa
CEM	cohort event monitoring
CHAI	Clinton Health Access Initiative
CoE	Centers of Excellence
CU	Compassionate Use
CXR	chest x-ray
DCS	Dried culture spot
Dlm	Delamanid
DR-TB	drug-resistant tuberculosis
DST	drug –susceptibility testing
EQA	External Quality Assessment
ERS	European Respiratory Society
FDC	fixed-dose combination
FIND	Foundation for Innovative New Diagnostics
GDF	Global Drug Facility
GDI	Global Drug resistant TB Initiative
GLI	Global Laboratory Initiative
GSM	Global System for Mobile Communications
GTB	Global TB Programme
HSP	Human Spirit Project
IRD	Interactive Research and Development
LAM	lipoarabinomannan
LAMP	Loop mediated isothermal amplification
LMICs	Lower middle income countries
LPA	Line probe assay
LTBI	latent tuberculosis infection
MDR-TB	multidrug-resistant tuberculosis
NAAT	nucleic acid amplification test
NFM	New Funding Model
NTP	National TB Programme
PEPFAR	United States President’s Emergency Plan for AIDS Relief
PLHIV	People living with HIV/AIDS
PMDT	programmatic management of drug-resistant tuberculosis
POC	Point-of-care
PV	Pharmacovigilance
QMS	quality management system
RESIST TB	Research Excellence to Stop TB Resistance
rGLC	regional Green Light Committee
RR-TB	Rifampicin resistant tuberculosis
SCM	Supply Chain Management
SLD	second-line drugs
SLIPTA	Strengthening Laboratory Management Towards Accreditation
SLMTA	Stepwise Laboratory Quality Improvement Process Towards Accreditation
SRL	Supranational Reference Laboratory
STAT	Scale-up Treatment Action Team
SWIFT	Society Working on Implementation to Fight TB
TB	tuberculosis
TB/HIV	tuberculosis/human immunodeficiency virus
TPP	target product profile
TRP	Technical Review Panel
UNITAID	Innovative Financing to Shape Markets for HIV/AIDS, Malaria and Tuberculosis
USAID	United States Agency for international Development
VL	Viral load
WHO	World Health Organization
XDR -TB	Extensively drug-resistant tuberculosis